Abstract 4368960: High-Intensity Statin Therapy Improves Outcomes Even After LDL-C Goal Achievement in Chronic Coronary Syndrome

Introduction: Current guidelines recommend a "treat to target" approach for lipid-lowering therapy in patients with chronic coronary syndrome (CCS), achieving the low-density lipoprotein cholesterol (LDL-C) levels target based on individual patient risk. However, it remains unclear whether the use of high intensity statins or non-high intensity statins to achieve the LDL-C goal in patients with CCS after percutaneous coronary intervention (PCI). Aim: We investigated the association between statin intensity and cardiovascular outcomes in patients who achieved LDL-C targets after PCI. Methods: A total of 455 Japanese patients with CCS who achieved an LDL-C level < 70mg/dL after PCI were enrolled. We divided patients into 4 groups according to the LDL-C levels and statin intensity prescribed after PCI: LDL-C < 55mg/dL with high intensity statins group (n = 81), LDL<55mg/dL with non-high intensity statins group (n = 170), LDL 55-70 mg/dL with high intensity statins group (n = 55), and LDL 55-70 mg/dl with non-high intensity statins group (n = 149). High-intensity statins were defined as the maximum approved doses of strong statins in Japan. Cardiovascular outcomes were defined as a composite of cardiovascular events, including cardiovascular death, acute coronary syndrome, stroke, and revascularization. Results: The mean age of the current study population was 73 years, and 75% were male. Among both achieved LDL-C goal groups, there was no significant difference in LDL-C levels between high intensity statins group and non-high intensity statins group (LDL-C < 55mg/dL: 43 ± 9 mg/d L vs. 43 ± 9 mg/d L; LDL-C 55-70 mg/d L: 62 ± 4 mg/d L vs. 61 ± 4 mg/d L). Kaplan-Meier survival analysis revealed a significantly lower incidence of cardiovascular events in the high intensity statins groups than the non-high intensity statins groups (log-rank test < 0.02) (Figure). Conclusions: Among patients with CCS who achieved LDL-C goal after PCI, high-intensity statin therapy was associated with a lower incidence of major adverse cardiovascular events compared to non-high-intensity statin therapy, regardless of the achieved LDL-C level.

Authors

Institutions

Publication Details

Journal
Circulation
Published
2025-11-03
DOI
https://doi.org/10.1161/circ.152.suppl_3.4368960
Primary Topic
Lipoproteins and Cardiovascular Health
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract 4368960: High-Intensity Statin Therapy Improves Outcomes Even After LDL-C Goal Achievement in Chronic Coronary Syndrome

Kosuke Tsuda, Yohei Yamauchi, Hirofumi Kusumoto, Hideaki Morita et al.
Circulation
Lipoproteins and Cardiovascular Health
article

Abstract 4368960: High-Intensity Statin Therapy Improves Outcomes Even After LDL-C Goal Achievement in Chronic Coronary Syndrome

Kosuke Tsuda, Yohei Yamauchi, Hirofumi Kusumoto, Hideaki Morita, Kazushi Sakane, Kenta Sakaguchi, Yumiko Kanzaki, Tomohiro Fujisaka, Mariko Shiba, SHIMPEI FUJIOKA, Daisuke Shishikura
article en

Abstract

Introduction: Current guidelines recommend a "treat to target" approach for lipid-lowering therapy in patients with chronic coronary syndrome (CCS), achieving the low-density lipoprotein cholesterol (LDL-C) levels target based on individual patient risk. However, it remains unclear whether the use of high intensity statins or non-high intensity statins to achieve the LDL-C goal in patients with CCS after percutaneous coronary intervention (PCI). Aim: We investigated the association between statin intensity and cardiovascular outcomes in patients who achieved LDL-C targets after PCI. Methods: A total of 455 Japanese patients with CCS who achieved an LDL-C level < 70mg/dL after PCI were enrolled. We divided patients into 4 groups according to the LDL-C levels and statin intensity prescribed after PCI: LDL-C < 55mg/dL with high intensity statins group (n = 81), LDL<55mg/dL with non-high intensity statins group (n = 170), LDL 55-70 mg/dL with high intensity statins group (n = 55), and LDL 55-70 mg/dl with non-high intensity statins group (n = 149). High-intensity statins were defined as the maximum approved doses of strong statins in Japan. Cardiovascular outcomes were defined as a composite of cardiovascular events, including cardiovascular death, acute coronary syndrome, stroke, and revascularization. Results: The mean age of the current study population was 73 years, and 75% were male. Among both achieved LDL-C goal groups, there was no significant difference in LDL-C levels between high intensity statins group and non-high intensity statins group (LDL-C < 55mg/dL: 43 ± 9 mg/d L vs. 43 ± 9 mg/d L; LDL-C 55-70 mg/d L: 62 ± 4 mg/d L vs. 61 ± 4 mg/d L). Kaplan-Meier survival analysis revealed a significantly lower incidence of cardiovascular events in the high intensity statins groups than the non-high intensity statins groups (log-rank test < 0.02) (Figure). Conclusions: Among patients with CCS who achieved LDL-C goal after PCI, high-intensity statin therapy was associated with a lower incidence of major adverse cardiovascular events compared to non-high-intensity statin therapy, regardless of the achieved LDL-C level.

CirculationVol. 152(Suppl_3)
Osaka University of Pharmaceutical Sciences (JP)
Openalex Percentile: Top 50%
Lipoproteins and Cardiovascular Health
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.